Roderick van den Bergh

Urologist in Erasmus MC and Anser prostate cancer network, Rotterdam, Netherlands. Prostate cancer care is about the art of omission.

[Roderick van den Bergh @roodvdb]

Targeted prostate biopsy may overestimate ISUP GG when compared to systematic biopsy, but this mainly occurs in smaller lesions. https://t.co/ljXjX1vSbG
@EAU_YAUProstate @Uroweb

[Roderick van den Bergh @roodvdb]

@declangmurphy Target Bx ISUP GG 2 ≈ Systematic Bx ISUP 1

[Roderick van den Bergh @roodvdb]

@gu_onc @Uroweb @declangmurphy @RenuEapen Please check out the latest @gu_onc podcast covering #EAU25, including discussion on the pros and cons of the @neurosafeproof trial. Thanks for having me @declangmurphy! @EAU_YAUProstate @Uroweb @CanUrolAssoc @UrologieNL

[Roderick van den Bergh @roodvdb]

@veerukasi @TheLancetOncol 👍 Congrats! Great study providing insight in a field with low level of evidence! @Uroweb @gu_onc @EAU_YAUProstate

[Roderick van den Bergh @roodvdb]

@JGomezRivas @UrologiaClinico @IIS_IdISSC @anestesiaHCSC @iClinicoMadrid @JesusMorenosier @juliomayol @ortegapolledo @InfoAeu So that’s where you were!

[Roderick van den Bergh @roodvdb]

@veerukasi @TheLancetOncol 🛎️ Beware of bias! Men were NOT blinded to nerve-sparing status! @gu_onc @Uroweb @EAU_YAUProstate @urotoday

[Roderick van den Bergh @roodvdb]

@deberli Looking forward!

[Roderick van den Bergh @roodvdb]

Thanks for inviting me to the outstanding #apcc24 in my old fellowship city #Melbourne! @phildundee @MarcDiocera @DrBenTran @DrDanielMoon @uroweb @EAU_YAUProstate @IMRASurgical

[Roderick van den Bergh @roodvdb]

@DrMarniqueB 👋

[Roderick van den Bergh @roodvdb]

@JGomezRivas @Uroweb @EAUYAUrology @JLVasquez82 @eau_yuo @veerukasi @NDowJames @ameliapietr1 @AngeloTerrito @dr_rajwa @PheVeronique @Cacciamani_MD @Ric_Campi Forever young

[Roderick van den Bergh @roodvdb]

@AustProstate Looking very much forward to join #apcc24 in Melbourne! @uroweb @EAU_YAUProstate

[Roderick van den Bergh @roodvdb]

@bavilima @JGomezRivas The advantage of upfront combination therapy may be questioned in some subgroups, especially at lower risk spectrum.

[Roderick van den Bergh @roodvdb]

@TheGiesen @joniau @EAU_YAUProstate @Uroweb @ESRUrology @EAUYAUrology @eau_yuo @GGandaglia @dr_rajwa Congrats!

[Roderick van den Bergh @roodvdb]

@PheVeronique @EurUrolOpen @sproietti81 @Walzjc @EUplatinum @JimCatto @UrowebESU @eau_yuo @EAUYAUrology @MarkusGraefen @RassweilerJens @AStenzl @u_capitanio @evanliats @LoebStacy @PorpigliaF @qdtrinh @heinvanpoppel @declangmurphy Great team 💫

[Roderick van den Bergh @roodvdb]

@joniau @JGomezRivas @Ecastromarcos @declangmurphy @ZilliThomas #uroonco24 @uroweb

[Roderick van den Bergh @roodvdb]

To consider when applying one-size-fits-all upfront combination therapy in M+HSPC:
- Undertreated trial control arms
- Mismatch age in real-life and trials
- Increase CV toxicity
Postpone intensification of therapy until CRPC?
@AlexSherryMD @LauraBukavinaMD @UroTaji

[Roderick van den Bergh @roodvdb]

@StrijbosMichiel

[Roderick van den Bergh @roodvdb]

🚧 Adding ARSI to ADT for M+ PCa gives additional risk CV-events. For which patients does the benefit of upfront combination Tx tip over to a risk and sequenced initiation at CRPC may be preferable? @BertrandTOMBAL @Silke_Gillessen @NivenMehra @dr_rajwa @DrBenTran @Ecastromarcos

[Roderick van den Bergh @roodvdb]

@KariTikkinen @cgratzke @EurUrolFocus @declangmurphy @EUplatinum @Uroweb @helsinkiuni @HelsinkiUniMed @HUS_fi @Uniklinik_Fr @GuyattGH @Prof_Nick_James @veerukasi @EBMUrology Great summer reads ☀️

[Roderick van den Bergh @roodvdb]

@DrShakuriRad Get some more info on the case?